



RECEIVED

Express Mail No.: EL 501 639 249 US

JUN 26 2001

TECH CENTER 1600/2900

Sheet 1 of 1

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-134	09/750,972
APPLICANT	
Srivastava, Pramod K.	
FILING DATE	GROUP
12/28/00	1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
							6/2/00

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
LY	DK	WO 94/14976	7/7/94	PCT			YES NO
LY	DL	WO 99/50303	10/7/99	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	Christy L HV	DATE CONSIDERED	5/23/02
----------	--------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUPPLEMENTAL LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. 8449-134-999	APPLICATION NO. 09/750,972
			APPLICANT Srivastava, Pramod K.	
FILING DATE 12/28/00		GROUP 1645		

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CY	DM	5,968,526	10/19/99				6/07/95
CY	DN	US 2002/0001841 A1	1/03/02				6/25/99
CY	DO	6,156,311	12/05/00				7/26/96

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES NO	
CY	DP	WO 00/38760	7/6/00	PCT				
CY	DQ	WO 00/03003	1/20/00	PCT				
CY	DR	WO 98/42752	10/01/98	PCT				
CY	DS	WO 00/34494	6/15/00	PCT				
CY	DT	WO 98/46739	7/23/97	PCT				X
CY	DU	WO 97/04794	2/13/97	PCT				
CY	DV	WO 00/46246	8/10/00	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CY	DW	Agostoni et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.
CY	DX	Bednar et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.
CY	DY	Collen et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.
CY	DZ	Hanover et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.
CY	EA	Hertz et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.
CY	EB	Hey et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.
CY	EC	Horn et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.
CY	ED	Huang et al., 1996, "The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product", Proc. Natl. Acad. Sci. USA. 93: 9730-9735.
CY	EE	Hughes et al., 1981, "Characterization of plasma membrane proteins identified by monoclonal antibodies", J. of Biol./ Chem. 256(2): 664-671.

CY	EF	Isaacs et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.
CY	EG	Katsutani et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol. 19(4):555-62.
CY	EH	Kim et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
CY	EI	Kimber et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
CY	EJ	Moestrup et al., 1990, "Immunocytochemical identification of the human alpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen", Exper. Cell Res. 190: 195-203.
CY	EK	Opekun et al., 1999, "Novel therapies for Helicobacter pylori infection." Aliment Pharmacol Ther. 13(1):35-42.
CY	EL	Reed et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80.
CY	EM	Yamauchi et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.
CY	EN	Zimecki et al., 1998, "Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals." Arch Immunol Ther Exp (Warsz). 46(4):231-40.
CD	EO	Zimecki et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.
EXAMINER	<i>Christopher H Yen</i>	
	DATE CONSIDERED 5/23/02	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conference and not considered. Include copy of this form with next communication to applicant.